CF
MYGN icon

Corebridge Financial’s Myriad Genetics MYGN Stock Holding History

Corebridge Financial’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,748
Closed -$415K – 1750
2025
Q1 		$415K Sell
46,748
-919
-2% -$11K ﹤0.01% 1698
2024
Q4 		$654K Sell
47,667
-3,716
-7% -$68.6K ﹤0.01% 1539
2024
Q3 		$1.41M Sell
51,383
-533
-1% -$14.4K 0.01% 1197
2024
Q2 		$1.27M Buy
+51,916
New +$1.14M 0.01% 1216

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Corebridge Financial's MYGN Position: Q2 2025 in Review

Corebridge Financial sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 46,748 shares — an estimated $415K sold.

Corebridge Financial first reported a position in MYGN in Q2 2024 and held it in 4 quarters. The position peaked at $1.41M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Corebridge Financial reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 46,748 Myriad Genetics shares in Q2 2025, an estimated $415K.
  • Corebridge Financial first reported a position in Myriad Genetics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Myriad Genetics position peaked at $1.41M in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.